参丹活血胶囊联合DP方案治疗不可切除的老年晚期卵巢腺癌的临床研究

目的探讨参丹活血胶囊联合DP方案(多西他赛注射液和顺铂注射液)治疗不可切除的老年晚期卵巢腺癌的临床疗效。方法选取2016年1月—2017年5月绵阳市中心医院收治的不可切除的老年晚期卵巢腺癌患者82例为研究对象,采用随机数字表法将所有患者分为对照组和治疗组,每组各41例。对照组患者给予DP方案治疗,第1天静脉滴注多西他赛注射液,75 mg/m2;第1~3天静脉滴注顺铂注射液,70 mg/m2。治疗组在对照组治疗的基础上口服参丹活血胶囊,6粒/次,3次/d。每个疗程3周,两组患者均连续治疗4个疗程。评价两组患者近期临床疗效,同时比较治疗前后的生活质量评分、免疫功能指标和毒副反应。结果治疗后,对照组和治疗组的客观缓解率分别为60.9%、78.0%,疾病控制率分别为43.9%、58.5%,两组近期临床疗效比较差异有统计学意义(P0.05)。治疗后,两组功能状况评分、社会状况评分均显著升高,附加关注评分、情感状况评分、生理状况评分均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组生活质量评分改善情况明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组免疫球蛋白G(IgG)、免疫球蛋白M(IgM)、免疫球蛋白A(IgA)、CD3~+和CD4~+均显著增高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组免疫指标明显高于对照组,两组比较差异具有统计学意义(P0.05)。治疗期间,治疗组各项毒副反应发生率均显著低于对照组,两组比较差异具有统计学意义(P0.05)。结论参丹活血胶囊联合DP方案治疗不可切除的老年晚期卵巢癌具有较好的临床疗效,能够有效改善患者生活质量和免疫功能,毒副作用小,具有一定的临床推广应用价值。

Clinical study on Shendan Huoxue Capsules combined with DP scheme in treatment of elderly non-resectable advanced adenocarcinoma of ovary

Objective To explore the clinical effect of Shendan Huoxue Capsules combined with DP scheme (Docetaxel Injection and Cisplatin Injection) in treatment of elderly non-resectable advanced adenocarcinoma of ovary. Methods Patients (82 cases) with elderly non-resectable advanced adenocarcinoma of ovary in Mianyang Central Hospital from January 2016 to May 2017 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were given DP scheme, and were iv administered with Docetaxel Injection 75 mg/m² at the first day, then were iv administered with Cisplatin Injection 70 mg/m² from the first to third day. Patients in the treatment group were po administered with Shendan Huoxue Capsules on the basis of the control group, 6 grains/time, three times daily. A course had 3 weeks, and patients in two groups were treated for 4 courses. After treatment, the short-term efficacy was evaluated, and quality of life scores, immune function indexes, and toxic reaction in two groups before and after treatment were compared. Results After treatment, the objective remission rates in the control and treatment groups were 60.9% and 78.0%, respectively, and disease control rates in the control and treatment groups were 43.9% and 58.5%, respectively, and there was difference between two groups (P < 0.05). After treatment, functional status scores and social condition scores in two groups were significantly increased, but additional attention scores, emotional state scores, and physiological condition scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the quality of life scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of IgG, IgM, IgA, CD3⁺and CD4⁺ in treatment group were significantly increased, and the difference was significant in the same group (P < 0.05). And the immune function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). During the treatment, the incidence of toxic reaction in the treatment group was lower than that in the control group, and there was difference between two groups (P < 0.05).Conclusions Shendan Huoxue Capsules combined with DP scheme has clinical curative effect in treatment of elderly non-resectable advanced adenocarcinoma of ovary, can effectively improve the quality of life and the immune function, reduce the toxic reaction, which has a certain clinical application value.